Charles D. Searles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charles D. Searles has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Martina Weber
Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia; and
5 shared publicationsArshed A. Quyyumi
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, USA
4 shared publicationsHerman A. Taylor
Department of Medicine, Morehouse School of Medicine, Atlanta, USA
3 shared publicationsJeong Hwan Kim
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, USA
3 shared publicationsKimberly Rooney
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, USA
3 shared publicationsMeredith B. Baker
Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30322, USA
3 shared publications
Latest Publications
- 28 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (2)
Plasma Metabolomic Signatures of Mitochondrial Energetic Disruption in Severe Primary Graft Dysfunction After Heart Transplantation
Objectives: Heart transplant primary graft dysfunction, defined as severe ventricular dysfunction within 24 hours after allograft reperfusion, is the leading cause of early mortality following heart transplantation. This study used plasma metabolomics to identify metabolic signatures associated with severe primary graft dysfunction. Methods: This single-centre study collected blood samples from 60 adult heart transplant recipients 12 and 24 hours following graft reperfusion. Patients were categorized according to the International Society for Heart and Lung Transplantation guidelines. Samples underwent metabolomics analysis via liquid chromatography-mass spectrometry. Linear models for microarray data were used to identify the metabolic effects of primary graft dysfunction, time, and their interaction, with pathway enrichment analysis and focused analysis of identified metabolites to interpret biological patterns. Results: Among the 60 patients included in this study, 8 developed severe primary graft dysfunction. Severe primary graft dysfunction was associated with coordinated metabolic alterations central to cellular energetics, including altered amino acid and nitrogen handling, broad acylcarnitine accumulation, and selective perturbations of tricarboxylic acid cycle intermediates. Temporal analyses identified divergent metabolite trajectories between groups, with succinate demonstrating the most pronounced divergence over time, reflecting failure to normalize central energy metabolism in severe primary graft dysfunction. Redox-related metabolites demonstrated patterns consistent with activation of antioxidant buffering. Conclusions: Severe primary graft dysfunction is characterized by a failure to restore cellular energy metabolism, reflected by coordinated upstream substrate accumulation and a distinct temporal pattern of succinate elevation. As an established metabolic signature of ischaemia-reperfusion injury, the succinate trajectory provides a biologically plausible link between impaired energetic recovery and downstream oxidative stress. Although exploratory, these findings support a coherent metabolic framework distinguishing recovery from persistent energetic stress in severe primary graft dysfunction.
- 28 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (2)
Plasma Metabolomic Signatures of Mitochondrial Energetic Disruption in Severe Primary Graft Dysfunction After Heart Transplantation
Objectives: Heart transplant primary graft dysfunction, defined as severe ventricular dysfunction within 24 hours after allograft reperfusion, is the leading cause of early mortality following heart transplantation. This study used plasma metabolomics to identify metabolic signatures associated with severe primary graft dysfunction. Methods: This single-centre study collected blood samples from 60 adult heart transplant recipients 12 and 24 hours following graft reperfusion. Patients were categorized according to the International Society for Heart and Lung Transplantation guidelines. Samples underwent metabolomics analysis via liquid chromatography-mass spectrometry. Linear models for microarray data were used to identify the metabolic effects of primary graft dysfunction, time, and their interaction, with pathway enrichment analysis and focused analysis of identified metabolites to interpret biological patterns. Results: Among the 60 patients included in this study, 8 developed severe primary graft dysfunction. Severe primary graft dysfunction was associated with coordinated metabolic alterations central to cellular energetics, including altered amino acid and nitrogen handling, broad acylcarnitine accumulation, and selective perturbations of tricarboxylic acid cycle intermediates. Temporal analyses identified divergent metabolite trajectories between groups, with succinate demonstrating the most pronounced divergence over time, reflecting failure to normalize central energy metabolism in severe primary graft dysfunction. Redox-related metabolites demonstrated patterns consistent with activation of antioxidant buffering. Conclusions: Severe primary graft dysfunction is characterized by a failure to restore cellular energy metabolism, reflected by coordinated upstream substrate accumulation and a distinct temporal pattern of succinate elevation. As an established metabolic signature of ischaemia-reperfusion injury, the succinate trajectory provides a biologically plausible link between impaired energetic recovery and downstream oxidative stress. Although exploratory, these findings support a coherent metabolic framework distinguishing recovery from persistent energetic stress in severe primary graft dysfunction.
- 15 December 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (4) , 760-771
Recipient plasma metabolomics as a predictor of heart transplant severe primary graft dysfunction
- 15 December 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (4) , 760-771
Recipient plasma metabolomics as a predictor of heart transplant severe primary graft dysfunction
- Open Access
- 20 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Metabolomic signatures of ideal cardiovascular health in black adults
Plasma metabolomics profiling is an emerging methodology to identify metabolic pathways underlying cardiovascular health (CVH). The objective of this study was to define metabolomic profiles underlying CVH in a cohort of Black adults, a population that is understudied but suffers from disparate levels of CVD risk factors. The Morehouse-Emory Cardiovascular (MECA) Center for Health Equity study cohort consisted of 375 Black adults (age 53 ± 10, 39% male) without known CVD. CVH was determined by the AHA Life’s Simple 7 (LS7) score, calculated from measured blood pressure, body mass index (BMI), fasting blood glucose and total cholesterol, and self-reported physical activity, diet, and smoking. Plasma metabolites were assessed using untargeted high-resolution metabolomics profiling. A metabolome wide association study (MWAS) identified metabolites associated with LS7 score after adjusting for age and sex. UsingMummichogsoftware, metabolic pathways that were significantly enriched in metabolites associated with LS7 score were identified. Metabolites representative of these pathways were compared across clinical domains of LS7 score and then developed into a metabolomics risk score for prediction of CVH. We identified novel metabolomic signatures and pathways associated with CVH in a cohort of Black adults without known CVD. Representative and highly prevalent metabolites from these pathways included glutamine, glutamate, urate, tyrosine and alanine, the concentrations of which varied with BMI, fasting glucose, and blood pressure levels. When assessed in conjunction, these metabolites were independent predictors of CVH. One SD increase in the novel metabolomics risk score was associated with a 0.88 higher LS7 score, which translates to a 10.4% lower incident CVD risk. We identified novel metabolomic signatures of ideal CVH in a cohort of Black Americans, showing that a core group of metabolites central to nitrogen balance, bioenergetics, gluconeogenesis, and nucleotide synthesis were associated with CVH in this population.
- 20 January 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Open AccessMetabolomic signatures of ideal cardiovascular health in black adults
Plasma metabolomics profiling is an emerging methodology to identify metabolic pathways underlying cardiovascular health (CVH). The objective of this study was to define metabolomic profiles underlying CVH in a cohort of Black adults, a population that is understudied but suffers from disparate levels of CVD risk factors. The Morehouse-Emory Cardiovascular (MECA) Center for Health Equity study cohort consisted of 375 Black adults (age 53 ± 10, 39% male) without known CVD. CVH was determined by the AHA Life’s Simple 7 (LS7) score, calculated from measured blood pressure, body mass index (BMI), fasting blood glucose and total cholesterol, and self-reported physical activity, diet, and smoking. Plasma metabolites were assessed using untargeted high-resolution metabolomics profiling. A metabolome wide association study (MWAS) identified metabolites associated with LS7 score after adjusting for age and sex. UsingMummichogsoftware, metabolic pathways that were significantly enriched in metabolites associated with LS7 score were identified. Metabolites representative of these pathways were compared across clinical domains of LS7 score and then developed into a metabolomics risk score for prediction of CVH. We identified novel metabolomic signatures and pathways associated with CVH in a cohort of Black adults without known CVD. Representative and highly prevalent metabolites from these pathways included glutamine, glutamate, urate, tyrosine and alanine, the concentrations of which varied with BMI, fasting glucose, and blood pressure levels. When assessed in conjunction, these metabolites were independent predictors of CVH. One SD increase in the novel metabolomics risk score was associated with a 0.88 higher LS7 score, which translates to a 10.4% lower incident CVD risk. We identified novel metabolomic signatures of ideal CVH in a cohort of Black Americans, showing that a core group of metabolites central to nitrogen balance, bioenergetics, gluconeogenesis, and nucleotide synthesis were associated with CVH in this population.
- Top Cited PapersOpen Access
- 11 January 2024
- Published by Springer Nature in Current Cardiology Reports
- Vol. 26 (2) , 51-60
MicroRNAs and Cardiovascular Disease Risk
Purpose of Review: MicroRNAs (miRNAs)—short, non-coding RNAs—play important roles in almost all aspects of cardiovascular biology, and changes in intracellular miRNA expression are indicative of cardiovascular disease development and progression. Extracellular miRNAs, which are easily measured in blood and can be reflective of changes in intracellular miRNA levels, have emerged as potential non-invasive biomarkers for disease. This review summarizes current knowledge regarding miRNAs as biomarkers for assessing cardiovascular disease risk and prognosis.Recent Findings: Numerous studies over the last 10–15 years have identified associations between extracellular miRNA profiles and cardiovascular disease, supporting the potential use of extracellular miRNAs as biomarkers for risk stratification. However, clinical application of extracellular miRNA profiles has been hampered by poor reproducibility and inter-study variability that is due largely to methodological differences between studies.Summary: While recent studies indicate that circulating extracellular miRNAs are promising biomarkers for cardiovascular disease, evidence for clinical implementation is lacking. This highlights the need for larger, well-designed studies that use standardized methods for sample preparation, miRNA isolation, quantification, and normalization.
- 11 January 2024
- Published by Springer Nature in Current Cardiology Reports
- Vol. 26 (2) , 51-60
Top Cited PapersOpen AccessMicroRNAs and Cardiovascular Disease Risk
Purpose of Review: MicroRNAs (miRNAs)—short, non-coding RNAs—play important roles in almost all aspects of cardiovascular biology, and changes in intracellular miRNA expression are indicative of cardiovascular disease development and progression. Extracellular miRNAs, which are easily measured in blood and can be reflective of changes in intracellular miRNA levels, have emerged as potential non-invasive biomarkers for disease. This review summarizes current knowledge regarding miRNAs as biomarkers for assessing cardiovascular disease risk and prognosis.Recent Findings: Numerous studies over the last 10–15 years have identified associations between extracellular miRNA profiles and cardiovascular disease, supporting the potential use of extracellular miRNAs as biomarkers for risk stratification. However, clinical application of extracellular miRNA profiles has been hampered by poor reproducibility and inter-study variability that is due largely to methodological differences between studies.Summary: While recent studies indicate that circulating extracellular miRNAs are promising biomarkers for cardiovascular disease, evidence for clinical implementation is lacking. This highlights the need for larger, well-designed studies that use standardized methods for sample preparation, miRNA isolation, quantification, and normalization.
- 5 January 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (1) , 97-99
Shedding Light on the Roles of Ceramide in Human Microvascular Function
- 5 January 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (1) , 97-99
Shedding Light on the Roles of Ceramide in Human Microvascular Function
- Open Access
- 27 March 2023
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 8 (3) , 298-300
Generating a Buzz About a New Treatment for Right Ventricular Failure
- 27 March 2023
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 8 (3) , 298-300
Open AccessGenerating a Buzz About a New Treatment for Right Ventricular Failure
- Open Access
- 1 December 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (12) , ofac641
The US Department of Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-Threatening Diseases (VA SHIELD): A Biorepository Addressing National Health Threats
Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has demonstrated the need to share data and biospecimens broadly to optimize clinical outcomes for US military Veterans. Methods: In response, the Veterans Health Administration established VA SHIELD (Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases), a comprehensive biorepository of specimens and clinical data from affected Veterans to advance research and public health surveillance and to improve diagnostic and therapeutic capabilities. Results: VA SHIELD now comprises 12 sites collecting de-identified biospecimens from US Veterans affected by SARS-CoV-2. In addition, 2 biorepository sites, a data processing center, and a coordinating center have been established under the direction of the Veterans Affairs Office of Research and Development. Phase 1 of VA SHIELD comprises 34 157 samples. Of these, 83.8% had positive tests for SARS-CoV-2, with the remainder serving as contemporaneous controls. The samples include nasopharyngeal swabs (57.9%), plasma (27.9%), and sera (12.5%). The associated clinical and demographic information available permits the evaluation of biological data in the context of patient demographics, clinical experience and management, vaccinations, and comorbidities. Conclusions: VA SHIELD is representative of US national diversity with a significant potential to impact national healthcare. VA SHIELD will support future projects designed to better understand SARS-CoV-2 and other emergent healthcare crises. To the extent possible, VA SHIELD will facilitate the discovery of diagnostics and therapeutics intended to diminish COVID-19 morbidity and mortality and to reduce the impact of new emerging threats to the health of US Veterans and populations worldwide.
- 1 December 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (12) , ofac641
Open AccessThe US Department of Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-Threatening Diseases (VA SHIELD): A Biorepository Addressing National Health Threats
Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has demonstrated the need to share data and biospecimens broadly to optimize clinical outcomes for US military Veterans. Methods: In response, the Veterans Health Administration established VA SHIELD (Science and Health Initiative to Combat Infectious and Emerging Life-threatening Diseases), a comprehensive biorepository of specimens and clinical data from affected Veterans to advance research and public health surveillance and to improve diagnostic and therapeutic capabilities. Results: VA SHIELD now comprises 12 sites collecting de-identified biospecimens from US Veterans affected by SARS-CoV-2. In addition, 2 biorepository sites, a data processing center, and a coordinating center have been established under the direction of the Veterans Affairs Office of Research and Development. Phase 1 of VA SHIELD comprises 34 157 samples. Of these, 83.8% had positive tests for SARS-CoV-2, with the remainder serving as contemporaneous controls. The samples include nasopharyngeal swabs (57.9%), plasma (27.9%), and sera (12.5%). The associated clinical and demographic information available permits the evaluation of biological data in the context of patient demographics, clinical experience and management, vaccinations, and comorbidities. Conclusions: VA SHIELD is representative of US national diversity with a significant potential to impact national healthcare. VA SHIELD will support future projects designed to better understand SARS-CoV-2 and other emergent healthcare crises. To the extent possible, VA SHIELD will facilitate the discovery of diagnostics and therapeutics intended to diminish COVID-19 morbidity and mortality and to reduce the impact of new emerging threats to the health of US Veterans and populations worldwide.
- 5 December 2020
- Published by Elsevier in Annals of Epidemiology
- Vol. 65, 120.e1-120.e10
Neighborhood characteristics and ideal cardiovascular health among Black adults: results from the Morehouse-Emory Cardiovascular (MECA) Center for Health Equity
- 5 December 2020
- Published by Elsevier in Annals of Epidemiology
- Vol. 65, 120.e1-120.e10
Neighborhood characteristics and ideal cardiovascular health among Black adults: results from the Morehouse-Emory Cardiovascular (MECA) Center for Health Equity
- 8 October 2020
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 127 (9) , 1179-1181
Development of MicroRNA-Based Therapeutics for Vascular Disease
- 8 October 2020
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 127 (9) , 1179-1181
Development of MicroRNA-Based Therapeutics for Vascular Disease